Effects of Combination Oral Contraceptives on Bone Mineral Density and Metabolism in Perimenopausal Korean Women
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: A retrospective cohort study was conducted to evaluate the effects of combination oral contraceptives (COCs) on bone mineral density (BMD) and metabolism in perimenopausal Korean women.Methods: The study subjects comprised two groups. The COC group included 55 women who took low-dose COC for at least one year to control vasomotor symptoms. Another 55 women who had annual checkups without history of COC use served as controls. BMD and bone turnover markers were assessed periodically.Results: In the control group, 12-month BMD values at the lumbar spine (LS) and total hip (TH) significantly decreased with a greater magnitude at LS, and bone resorption (BR) and formation (BF) markers increased concurrently with a larger change in BR. COCs increased BMD at LS after 12 months and prevented BMD decline at TH. Multivariable linear regression revealed a significant difference in LS BMD between groups at 12 months. In the COC group, there were significant negative correlations between baseline BMD and Z-score at LS and corresponding changes at 12 months. COCs did not alter BR markers, whereas BF markers were significantly decreased at 3 months. Group comparison at 12 months, as tested with adjusted linear regression, disclosed significant differences in both BR and BF makers.Conclusions: Bone loss associated with activated bone turnover is evident during the menopausal transition, and COCs might prevent BMD decrease and suppress bone turnover markers in perimenopausal Korean women. Significant increase in LS BMD and decreases in BF makers suggest underlying mechanisms of greater impact on BF.
Abstract
Objectives: A retrospective cohort study was conducted to evaluate the effects of combination oral contraceptives (COCs) on bone mineral density (BMD) and metabolism in perimenopausal Korean women.Methods: The study subjects comprised two groups. The COC group included 55 women who took low-dose COC for at least one year to control vasomotor symptoms. Another 55 women who had annual checkups without history of COC use served as controls. BMD and bone turnover markers were assessed periodically.Results: In the control group, 12-month BMD values at the lumbar spine (LS) and total hip (TH) significantly decreased with a greater magnitude at LS, and bone resorption (BR) and formation (BF) markers increased concurrently with a larger change in BR. COCs increased BMD at LS after 12 months and prevented BMD decline at TH. Multivariable linear regression revealed a significant difference in LS BMD between groups at 12 months. In the COC group, there were significant negative correlations between baseline BMD and Z-score at LS and corresponding changes at 12 months. COCs did not alter BR markers, whereas BF markers were significantly decreased at 3 months. Group comparison at 12 months, as tested with adjusted linear regression, disclosed significant differences in both BR and BF makers.Conclusions: Bone loss associated with activated bone turnover is evident during the menopausal transition, and COCs might prevent BMD decrease and suppress bone turnover markers in perimenopausal Korean women. Significant increase in LS BMD and decreases in BF makers suggest underlying mechanisms of greater impact on BF.
참고문헌 (21)
- Cauley JA, "Estrogen and bone health in men and women", Steroids, 99(Pt A), pp.11~15 (2015)
- Jackson RD, "Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy : results from the women's health initiative randomized trial", J Bone Miner Res, 21, pp.817~828 (2006)
- Riggs BL, "Rates of bone loss in the appendicular and axial skeletons of women. Evidence of substantial vertebral bone loss before menopause", J Clin Invest, 77, pp.1487~1491 (1986)
- Prior JC, "Progesterone for the prevention and treatment of osteoporosis in women", Climacteric, 21, pp.366~374 (2018)
- Greendale GA, "Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort : results from the Study of Women's Health Across the Nation(SWAN)", J Bone Miner Res, 27, pp.111~118 (2012)
- Scholes D, "Oral contraceptive use and fracture risk around the menopausal transition", Menopause, 23, pp.166~174 (2016)
- Liu SL, "Effect of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women : a systematic review", Br J Sports Med, 40, pp.11~24 (2006)
- Riggs BL, "Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites", J Bone Miner Res, 19, pp.1945~1954 (2004)
- Riggs BL, "A population-based assessment of rates of bone loss at multiple skeletal sites : evidence for substantial trabecular bone loss in young adult women and men", J Bone Miner Res, 23, pp.205~214 (2008)
- Crandall CJ, "Serum sex steroid levels and longitudinal changes in bone density in relation to the final menstrual period", J Clin Endocrinol Metab, 98, pp.E654~E663 (2013)
- Taylor HS, "Speroff's clinical gynecologic endocrinology and infertility", pp.580~751 (2020), Wolters Kluwer
- Recker R, "Characterization of perimenopausal bone loss : a prospective study", J Bone Miner Res, 15, pp.1965~1973 (2000)
- Seifert-Klauss V, "Bone loss in premenopausal, perimenopausal and postmenopausal women : results of a prospective observational study over 9 years", Climacteric, 15, pp.433~440 (2012)
- Prior JC, "Cyclic medroxyprogesterone treatment increases bone density : a controlled trial in active women with menstrual cycle disturbances", Am J Med, 96, pp.521~530 (1994)
- Tremollieres FA, "Progesterone and promegestone stimulate human bone cell proliferation and insulin-like growth factor-2 production", Acta Endocrinol (Copenh), 126, pp.329~337 (1992)
- Gambacciani M, "Longitudinal evaluation of perimenopausal vertebral bone loss : effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism", Obstet Gynecol, 83, pp.392~396 (1994)
- Gambacciani M, "Longitudinal evaluation of perimenopausal femoral bone loss : effects of a low-dose oral contraceptive preparation on bone mineral density and metabolism", Osteoporos Int, 11, pp.544~548 (2000)
- Gambacciani M, "Longitudinal evaluation of perimenopausal bone loss : effects of different low dose oral contraceptive preparations on bone mineral density", Maturitas, 54, pp.176~180 (2006)
- Crandall CJ, "Presence of vasomotor symptoms is associated with lower bone mineral density : a longitudinal analysis", Menopause, 16, pp.239~246 (2009)
- Cauley JA, "Bone resorption and fracture across the menopausal transition: the Study of Women's Health Across the Nation", Menopause, 19, pp.1200~1207 (2012)
- Dombrowski S, "Oral contraceptive use and fracture risk-a retrospective study of 12, 970 women in the UK", Osteoporos Int, 28, pp.2349~2355 (2017)